Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)
Fresenius SE & Co. KGaA / Key word(s): Forecast/Strategic Company Decision
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius expects Group organic revenue (base 2022: €40,840 million) to grow in a low- to mid-single-digit percentage range. Group constant currency EBIT before special items (base 2022: €3,727 million*) is expected to remain broadly flat or decline up to a high-single-digit percentage rate. The range of the decrease compared to the previous year is mainly due to a challenging business environment at Fresenius Medical Care. Excluding Fresenius Medical Care, the Group constant currency EBIT before special items (base 2022: €2,187 million) is expected to remain broadly flat or decline up to a mid-single-digit percentage rate.
21-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Fresenius SE & Co. KGaA
61352 Bad Homburg v.d.H.
+49 (0)6172 608-2485
+49 (0)6172 608-2488
Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID:
End of Announcement
EQS News Service